SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : CORONA Remedies Ltd

BSE: 544644 NSE: CORONA ISIN: INE02ZQ01018
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does CORONA Remedies Ltd belong to?
CORONA Remedies Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is CORONA Remedies Ltd a good quality company?
CORONA Remedies Ltd is a average quality company, based on a somewhat consistent 10 year financial track record.
Q.3 Is CORONA Remedies Ltd undervalued or overvalued?
CORONA Remedies Ltd appears Overvalued, as its key valuation ratios are above with their past averages.
Q.4 Is CORONA Remedies Ltd a good buy now?
CORONA Remedies Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of CORONA Remedies Ltd?
CORONA Remedies Ltd revenue growth is 17.9% for FY-2025 , which is above its 5 year CAGR of 0% , indicating faster growth.
Q.2 Gross Profit margin of CORONA Remedies Ltd?
CORONA Remedies Ltd Gross profit margin which is the profit after deduction of direct costs, is 19.3% for FY-2025 , which is above its 5 year median of 14.5% , indicating increasing margins.
Q.3 Operating Profit Margin of CORONA Remedies Ltd?
CORONA Remedies Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 20.12% for FY-2025 , which is above its 5 year median of 15.37% indicating increasing margins.
Q.4 Net Profit Margin of CORONA Remedies Ltd?
CORONA Remedies Ltd Net Profit Margin is 12.46% for FY-2025 , is above with its 5 year median of 9.58%, indicating increasing margins.
Current Level Historic Median
Gross Profit Margin 19.3 14.5
Operating Profit Margin 20.12 15.37
Net Profit Margin 12.46 9.58
Q.5 Return on Asset of CORONA Remedies Ltd?
CORONA Remedies Ltd Return on Asset is 15.76%, which is above its 5 year historical median of 11.97%, indicating improved asset utilization efficiency.
Q.6 Return on Equity (ROE) of CORONA Remedies Ltd?
CORONA Remedies Ltd Return on equity is 27.45% for FY-2025 , which is above its historical median of 20.73%, indicating the business is making better use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of CORONA Remedies Ltd?
CORONA Remedies Ltd Return on capital employed is 32.55% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 13.5%, indicating value creation.
Q.8 Cash conversion cycle of CORONA Remedies Ltd?
CORONA Remedies Ltd Cash conversion cycle is 8 days, below its historical median of 13 days, indicating improved working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 1.29 1.29
ROE 27.45 20.73
ROCE 32.55 25.94
Cash Conversion Cycle 8 days 13 days
Q.9 Debt to Equity ratio of CORONA Remedies Ltd?
CORONA Remedies Ltd Debt-to-Equity ratio is 0.10 , which is lower with the industry average of 0.15 , indicating lower debt levels in the industry.
Q.10 Debt to cash flow from operations of CORONA Remedies Ltd?
CORONA Remedies Ltd Debt to cash flow from operations is 0.33 , which is at a healthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of CORONA Remedies Ltd?
Promoters hold 69.00% of the CORONA Remedies Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of CORONA Remedies Ltd vs industry peers?
CORONA Remedies Ltd revenue CAGR is 0.00% , compared to the industry median CAGR of 5.54% , indicating slower growth and losing its market share.
Profit Metrics
Current Level Industry Median
Revenue 1,196.4 137.1
Gross Profit 230.8 15.1
Operating Profit 240 16
Net Profit 149 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 1.29 0.8
ROE 27.45 8.91
ROCE 32.55 11.59
Cash Conversion Cycle (days) 7.68 76

Valuation & price assessment

Q.1 Stock return of CORONA Remedies Ltd over the last decade?
Over the last - year(s), the stock has delivered a CAGR of N/A% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price - - - -
Q.3 Valuation ratios of CORONA Remedies Ltd vs historical?
The current P/E is lower that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 64.59 65.74 40.28
Price to Book 13.75 13.99 2.77
Price to Sales 8.05 39.79 2.65
EV to EBITDA 39.09 0.00 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Natco Pharma
10. Eris Lifesciences
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×